PharmEasy is a consumer healthcare “super app” that meets customers’ healthcare needs by giving them on-demand, home-delivered access to a variety of prescription, over-the-counter, and other consumer healthcare products, as well as extensive diagnostic test services and teleconsultations.

A total of Rs 6200 crore in new issues would be included in the IPO. A total of Rs 1929 crore would be used for prepayment or repayment from the proceeds of the IPO, and Rs 1259 crore will go toward funding measures to promote organic growth. The balance would go toward financing inorganic expansion.

PharmEasy IPO Valuation

According to two people with firsthand knowledge of the discussions, Indian drug and medical services startup PharmEasy is in talks with investors to fund $200 million at a value that might be 15% or even 25% lower than last year’s $5.1 billion.

Top 5 Competitors of PharmEasy

  • • Apollo 24/7.
  •  SastaSundar.
  •  Medlife International.
  •  NetmedsMarketplace.

Leave a Reply

Your email address will not be published. Required fields are marked *